



Regular Meeting of the
Santa Clara County Health Authority d.b.a. Santa Clara Family Health Plan
Pharmacy & Therapeutics Committee

Thursday, December 14, 2017
6:00 PM - 8:00 PM
210 E. Hacienda Avenue Campbell, CA 95008

MINUTES

Voting Committee Members	Specialty	Present (Y or N)
Jimmy Lin, MD	Internal Medicine	Y
Hao Bui, BS, PharmD	Community Pharmacy (Walgreens)	Y
Minh Thai, MD	Family Practice	N
Amara Balakrishnan, MD	Pediatrics	Y
Peter Nguyen, MD	Family Practice	N
Jesse Parashar-Rokicki, MD	Family Practice	N
Narinder Singh, PharmD	Health System Pharmacy (SCVMC)	Y
Ali Alkoraishi, MD	Adult & Child Psychiatry	Y
Dolly Goel, MD	VHP Chief Medical Officer	N
Xuan Cung, PharmD	Pharmacy Supervisor (VHP)	Y
Johanna Liu, PharmD, MBA	SCFHP Director of Quality and Pharmacy	Y
Jeff Robertson, MD	SCFHP Chief Medical Officer	N

Non-Voting Committee Members	Specialty	Present (Y or N)
Lily Boris, MD	SCFHP Medical Director	N
Caroline Alexander	SCFHP Administrative Assistant, Medical Management	Y
Tami Otomo, PharmD	SCFHP Clinical Pharmacist	N
Duyen Nguyen, PharmD	SCFHP Clinical Pharmacist	Y
Dang Huynh, PharmD	SCFHP Pharmacy Manager	Y
Amy McCarty, PharmD	MedImpact Clinical Program Manager	Y
Dawn Davis	SCFHP Grievance and Appeals Consultant	Y (via telephone)
Tiffanie Pham, CPHT	SCFHP Pharmacy Coordinator	Y
Guests	Specialty	Present (Y or N)
Jade Vitug, PharmD	VHP Pharmacy Resident	Y

	Topic and Discussion	Follow-Up Action
1	Introductions The meeting convened at 6:10 PM. Introduced Duyen Nguyen, SCFHP Clinical Pharmacist, Tiffanie Pham, SCFHP Pharmacy Coordinator and guest Jade Vitug, Pharmacy Resident at Valley Health Plan.	
2	Past Meeting Minutes The SCFHP 3Q2017 P&T Minutes from September 21, 2017 were reviewed by the Committee as submitted.	Upon motion duly made and seconded, the SCFHP 3Q2017



		P&T Minutes from September 21, 2017 were approved as submitted and will be forwarded to the QI Committee and Board of Directors.
3	Public Comment	
	No public comment.	
4	Informational Updates	
	<p>Health Plan Updates Deferred until next committee meeting.</p> <p>Prescription Drug Prior Authorization or Step Therapy Exception Request Form (Revised Form 61-211) Dr. Huynh presented the update on Form 61-211. A memo was sent to providers via FAX blast and will be attached to prior authorization decisions in the next few weeks. DHCS requires form 61-211 which was revised December 2016 and became effective July 1, 2017. Effective January 1, 2018, the plan will no longer accept the old form.</p>	
	<p>Appeals & Grievances Ms. Davis presented the Appeals and Grievances report for Pharmacy and Part D. There was an increase in Medi-Cal appeals. Change in process, data is being collected through appeals department. Q2 2017 41% overturn rate, 55% upheld. Q3 2017 56% overturn rate, 20% upheld, 11% withdrawn. For Cal MediConnect Q3 Part C&D redeterminations have remained steady. Low during Q3: 4 in July, 8 in August, 7 in September. Part D redeterminations Q2: 50% overturned, 34% upheld, 8% withdrawn. Q3: 20% upheld, 30% overturned, 40% withdrawn.</p>	
	<p>Adjourn to Closed Session Committee adjourned to closed session at 6:42 p.m. to discuss the following items: Membership, Pharmacy Dashboard, Drug Utilization & Spend, Recommendations for Changes to SCFHP Cal MediConnect, Medi-Cal, Healthy Kids Formulary and Prior Authorization Criteria, Medical Pharmacy Prior Authorization Grid, DHCS Medi-Cal CDL Updates & Comparability, and New Drugs and Class Reviews.</p>	
5	Metrics & Financial Updates	
	<p>Membership Report Dr. Liu presented the membership report. Slight decline in Medi-Cal line of business membership. Slight increases in Cal MediConnect (CMC). Attribute the growth in CMC to more fully developing Medi-Care Outreach department. Outreach to our existing Medi-Cal population that are also full dual and may be eligible for CMC.</p>	
	Pharmacy Dashboard	



	<p>Dr. Huynh presented the Pharmacy Dashboard. For Medi-Cal line of business, prior authorization approval rate increased from 55% to 70% during the timeframe of September to October. 24 hour turnaround time is compliant at 100%. Expedited 24 hour turnaround time approval rate is from 62 to 77%. Interrater reliability done 10/19/2017. For Cal MediConnect line of business, prior authorization volume increased in the previous quarter. 72 hour turnaround time is 100%. Expedited increased from 58% to 68%. Met goal of CMR completion rate of 20% earlier than the previous calendar year. Percent shifted slightly, still on track to meet goal. Denied claims reviewed: 96%, on track with formulary submission to CMS.</p>	
	<p>Discussion and Recommendations for changes to SCFHP Cal MediConnect Formulary & Prior Authorization Criteria</p> <p>Dr. Huynh presented an overview of the MedImpact 3Q2017 P&T minutes as well as the MedImpact 4Q2017 P&T Part D Actions.</p>	<p>Upon motion duly made and seconded the MedImpact 3Q2017 P&T Minutes, and MedImpact 4Q2017 P&T Part D Actions were approved as submitted.</p>
	<p>Discussion and Recommendations for Changes to SCFHP Medi-Cal & Healthy Kids Formulary & Prior Authorization Criteria</p> <p>Formulary Modifications Dr. Huynh presented the formulary changes since the last P&T meeting. Of note: added Mavyret to formulary with prior authorization and quantity limit of 3/day. Added Vitamin D3 50,000 unit capsule to formulary. Added Tears Again, Lubrifresh PM, and Tears Naturale PM ophthalmic ointment products to formulary. Added Shingrix with age limit of greater than or equal to 50 years old and quantity limit. Remove Glatopa 20mg/ml from formulary. Added Makena 250mg/ml (1 ml vial) to formulary with prior authorization. Recommend: Add Leucovorin 25mg tablet to formulary. Remove Triamex ointment to formulary. Remove Zepatier from formulary.</p>	<p>Upon motion duly made and seconded, formulary modifications were approved as presented.</p>
	<p>Prior Authorization Criteria</p> <ul style="list-style-type: none"> - Dr. Nguyen presented the following PA criteria for approval by the committee: <ul style="list-style-type: none"> - Hepatitis C - Ciclopirox 8% - Non-formulary - Brand Name - Off-Label - Compounded Medications - General Criteria-UM Medical Drugs - Eosinophilic Asthma 	<p>Upon motion duly made and seconded, prior authorization criteria were approved as requested.</p>



	<ul style="list-style-type: none"> - Cotellic - Duragesic - Emend - Exelon - Farydak - Iressa - Keytruda - Lyrica - Marinol - Myrbetriq - Nebupent - Nexavar - Odomzo - Restasis - Revatio - Targretin - Temodar - Tymlos - Xarelto - Xolair - Zarxio 	
	<p>DHCS Medi-Cal CDL Updates & Comparability</p> <p>Dr. McCarty presented the DHCS Medi-Cal Updates and Comparability. For September 2017, two drugs added and one dosage form added. No proposed action for September 2017. For October 2017, one drug with strength removed. No proposed action for October 2017. For November 2017, one drug with quantity limit and fill limit. November 2017 propose add quantity limit and match CDL for Promethazine w/Phenylephrine and Codeine.</p>	<p>Upon motion duly made and seconded, all recommendations were approved and presented.</p>
	<p>New Drugs and Class Reviews</p> <p>New Drug Reviews</p> <p>Dr. McCarty presented the following new drug reviews:</p> <ul style="list-style-type: none"> - Shingrix –Add age limit to allow in 50 and older; add quantity limit of 2 doses per lifetime. Remove Zostavax from formulary. - Diabetes – Jardiance/Synjardy/Synjardy XR-Add to formulary, add step therapy (required trial of Metformin + oral/GLP-1RA), add quantity limit Jardiance & Synjardy XR 1/day, Synjardy 2/day - Diabetes-Januvia/Janumet/Janumet XR-remove from formulary - Car T Cell Therapies –Kymriah for pediatric, Yescarta for Adults; administered via single IV infusion bag 	<p>Upon motion duly made and seconded, all recommendations were approved as presented.</p>



	Drug Utilization and Spend Review Dr. McCarty presented the Drug Utilization and Spend Review report. Diabetes remains the top spend. Drop in infectious disease. Pulmonary arterial hypertension has doubled. A lot more utilization of calcium by members of Santa Clara Family Health Plan.	
	Reconvene in Open Session Committee reconvened to open session at 7:35 p.m.	
6	Discussion Items	
	Update on New Drugs and Generic Pipeline Informational Only	
7	Adjournment at 8:02 PM	